Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body'... Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany. Mehr anzeigen
In 33 heavily pretreated NSCLC EGFR wild-type (EGFRwt) patients the combination of AFM24 and atezolizumab shows an overall response rate (ORR) of 21% (6 confirmed responses, 1 response awaiting...
AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily...
MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard...
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory...
AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.13 | -11.5044247788 | 1.13 | 1.1348 | 0.9277 | 263002 | 1.0343145 | CS |
| 4 | -0.26 | -20.6349206349 | 1.26 | 1.54 | 0.9277 | 283769 | 1.17316025 | CS |
| 12 | -2.65 | -72.602739726 | 3.65 | 4.0413 | 0.9277 | 361073 | 1.88399662 | CS |
| 26 | -4.21 | -80.8061420345 | 5.21 | 5.48 | 0.9277 | 207183 | 2.34683705 | CS |
| 52 | -4.6 | -82.1428571429 | 5.6 | 8.95 | 0.9277 | 377796 | 5.38928256 | CS |
| 156 | -37.6 | -97.4093264249 | 38.6 | 51 | 0.9277 | 947378 | 18.03413667 | CS |
| 260 | -26.1 | -96.3099630996 | 27.1 | 117.4 | 0.9277 | 1191913 | 41.67011211 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
